Patents by Inventor David Dismuke

David Dismuke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AAV transfer cassette
    Patent number: 12611436
    Abstract: Described herein are AAV transfer cassettes and plasmids used in the production of recombinant adeno-associated viral (rAAV) vectors. The disclosed cassettes and plasmids comprise one or more transgenes having therapeutic efficacy in the amelioration, treatment and/or prevention of one or more diseases or disorders, such as Niemann-Pick Disease, type C1 (NPC1).
    Type: Grant
    Filed: October 16, 2020
    Date of Patent: April 28, 2026
    Assignee: Sarepta Therapeutics, Inc.
    Inventor: David Dismuke
  • ADENOVIRAL HELPER PLASMID
    Publication number: 20250019667
    Abstract: The present disclosure provides improved adenoviral helper plasmids for the production of recombinant adeno-associated viruses.
    Type: Application
    Filed: May 13, 2022
    Publication date: January 16, 2025
    Inventor: David Dismuke
  • Engineered untranslated regions (UTR) for AAV production
    Patent number: 12060567
    Abstract: The present disclosure describes methods and systems for use in the production of recombinant adeno-associated virus (rAAV) particles. In certain embodiments, the production process and system include engineered untranslated regions (UTR) which allow for the controlled expression of AAV capsid proteins, such as VP1, VP2 and VP3. In certain embodiments, the production process and system include engineered untranslated regions (UTR) which allow for the controlled expression of non-structural AAV replication proteins, such as Rep78 and Rep52.
    Type: Grant
    Filed: June 13, 2019
    Date of Patent: August 13, 2024
    Assignee: Voyager Therapeutics, Inc.
    Inventors: Luis Maranga, Sylvain Cecchini, David Dismuke
  • AAV TRANSFER CASSETTE
    Publication number: 20240226206
    Abstract: Described herein are AAV transfer cassettes and plasmids used in the production of recombinant adeno-associated viral (rAAV) vectors. The disclosed cassettes and plasmids comprise one or more transgenes having therapeutic efficacy in the amelioration, treatment and/or prevention of one or more diseases or disorders, such as Niemann-Pick Disease, type C1 (NPC1).
    Type: Application
    Filed: October 16, 2020
    Publication date: July 11, 2024
    Inventor: David DISMUKE
  • AAV TRANSFER CASSETTE
    Publication number: 20240131185
    Abstract: Described herein are AAV transfer cassettes and plasmids used in the production of recombinant adeno-associated viral (rAAV) vectors. The disclosed cassettes and plasmids comprise one or more transgenes having therapeutic efficacy in the amelioration, treatment and/or prevention of one or more diseases or disorders, such as Niemann-Pick Disease, type C1 (NPC1).
    Type: Application
    Filed: October 15, 2020
    Publication date: April 25, 2024
    Inventor: David DISMUKE
  • Adeno-associated viral vectors for treatment of Niemann-Pick Disease type-C
    Patent number: 11905523
    Abstract: Provided herein are gene therapy compositions and methods for treating, preventing, and/or curing NPC1. More specifically, the disclosure provides Adeno-associated virus (AAV) vectors for delivery of nucleic acids and nucleic acids (including AAV transfer cassettes) for treating, preventing, and/or curing NPC1.
    Type: Grant
    Filed: October 16, 2020
    Date of Patent: February 20, 2024
    Assignee: Ginkgo Bioworks, Inc.
    Inventors: Daniel McCoy, Garrett E. Berry, David Dismuke
  • ADENO-ASSOCIATED VIRAL VECTORS FOR TREATMENT OF NIEMANN-PICK DISEASE TYPE C
    Publication number: 20230392163
    Abstract: Provided herein are gene therapy compositions and methods for treating, preventing, and/or curing NPC1. More specifically, the disclosure provides Adeno-associated virus (AAV) vectors for delivery of nucleic acids and nucleic acids (including AAV transfer cassettes) for treating, preventing, and/or curing NPC1.
    Type: Application
    Filed: October 16, 2020
    Publication date: December 7, 2023
    Inventors: Daniel MCCOY, Garrett BERRY, David DISMUKE
  • METHODS AND COMPOSITIONS FOR TREATMENT OF FRAGILE X SYNDROME
    Publication number: 20230295654
    Abstract: Methods for alleviating symptoms in a Fragile X Syndrome (FXS) patient using adeno-associated viral (AAV) 9 viral particles encoding a wild-type human fragile X mental retardation 1 (FMR1) protein (human FMRP). Also provided herein are methods to determine suitable doses of AAV9 viral particles for a FXS patient to alleviate at least one symptom associated with FXS, as well as methods for monitoring treatment efficacy.
    Type: Application
    Filed: July 16, 2021
    Publication date: September 21, 2023
    Applicants: CHILDREN'S HOSPITAL MEDICAL CENTER, FORGE BIOLOGICS, INC.
    Inventors: Ernest PEDAPATI, Christina GROSS, Craig ERICKSON, David DISMUKE, Erandi Kanchana DE SILVA
  • METHODS AND SYSTEMS FOR PRODUCING AAV PARTICLES
    Publication number: 20220064671
    Abstract: The present disclosure describes methods and systems for use in the production of adeno-associated virus (AAV) particles, comprising recombinant adeno-associated virus (rAAV) particles. In certain embodiments, the production process and system use Sf9 insect cells as viral production cells. In certain embodiments, the production process and system use Baculoviral Expression Vectors (BEVs) and Baculoviral Infected Insect Cells (BIICs) in the production of AAV particles.
    Type: Application
    Filed: January 17, 2020
    Publication date: March 3, 2022
    Inventors: Luis Maranga, Christopher J. Morrison, Krishanu Mathur, Matthew Luther, Daniel S. Hurwit, Jacob J. Cardinal, Lori B. Karpes, Aditya Ansondaria, James Forster, David Dismuke, Robert Steininger
  • RECOMBINANT VIRAL VECTORS AND NUCLEIC ACIDS FOR PRODUCING THE SAME
    Publication number: 20210324418
    Abstract: Described herein are nucleic acids, AAV transfer cassettes and plasmids used in the production of recombinant adeno-associated viral (rAAV) vectors. The disclosed nucleic acids, cassettes and plasmids comprise sequences that express one or more transgenes having therapeutic efficacy in the amelioration, treatment and/or prevention of one or more diseases or disorders.
    Type: Application
    Filed: May 21, 2021
    Publication date: October 21, 2021
    Inventors: Darby Thomas, David Dismuke
  • ENGINEERED UNTRANSLATED REGIONS (UTR) FOR AAV PRODUCTION
    Publication number: 20210301305
    Abstract: The present disclosure describes methods and systems for use in the production of recombinant adeno-associated virus (rAAV) particles. In certain embodiments, the production process and system include engineered untranslated regions (UTR) which allow for the controlled expression of AAV capsid proteins, such as VP1, VP2 and VP3. In certain embodiments, the production process and system include engineered untranslated regions (UTR) which allow for the controlled expression of non-structural AAV replication proteins, such as Rep78 and Rep52.
    Type: Application
    Filed: June 13, 2019
    Publication date: September 30, 2021
    Inventors: Luis Maranga, Sylvain Cecchini, David Dismuke
  • AAV TRANSFER CASSETTE
    Publication number: 20210128652
    Abstract: Described herein are AAV transfer cassettes and plasmids used in the production of recombinant adeno-associated viral (rAAV) vectors. The disclosed cassettes and plasmids comprise one or more transgenes having therapeutic efficacy in the amelioration, treatment and/or prevention of one or more diseases or disorders, such as Niemann-Pick Disease, type C1 (NPC1).
    Type: Application
    Filed: October 16, 2020
    Publication date: May 6, 2021
    Inventor: David Dismuke
  • ADENO-ASSOCIATED VIRAL VECTORS FOR TREATMENT OF NIEMANN-PICK DISEASE TYPE-C
    Publication number: 20210115474
    Abstract: Provided herein are gene therapy compositions and methods for treating, preventing, and/or curing NPC1. More specifically, the disclosure provides Adeno-associated virus (AAV) vectors for delivery of nucleic acids and nucleic acids (including AAV transfer cassettes) for treating, preventing, and/or curing NPC1.
    Type: Application
    Filed: October 16, 2020
    Publication date: April 22, 2021
    Inventors: Daniel MCCOY, Garrett E. BERRY, David DISMUKE
  • INSECT CELL MANUFACTURED PARTIAL SELF-COMPLEMENTARY AAV GENOMES
    Publication number: 20210010028
    Abstract: The present disclosure is directed to parvovirus genomes; plasmid vectors encoding parvovirus genomes, and particles and populations thereof; as well as methods of their production and use.
    Type: Application
    Filed: March 6, 2019
    Publication date: January 14, 2021
    Inventors: Eric D. Horowitz, Sylvain Cecchini, Robert Steininger, David Dismuke, Christopher J. Morrison